Macrocyclic 1,2-Hydroxypyridinone-Based Chelators as Potential Ligands for Thorium-227 and Zirconium-89 Radiopharmaceuticals.

Thorium-227 (227Th) is an α-emitting radionuclide that has shown preclinical and clinical promise for use in targeted α-therapy (TAT), a type of molecular radiopharmaceutical treatment that harnesses high energy α particles to eradicate cancerous lesions. Despite these initial successes, there still exists a need for bifunctional chelators that can stably bind thorium in vivo. Toward this goal, we have prepared two macrocyclic chelators bearing 1,2-hydroxypyridinone groups. Both chelators can be synthesized in less than six steps from readily available starting materials, which is an advantage over currently available platforms. The complex formation constants (log ßmlh) of these ligands with Zr4+ and Th4+, measured by spectrophotometric titrations, are greater than 34 for both chelators, indicating the formation of exceedingly stable complexes. Radiolabeling studies were performed to show that these ligands can bind [227Th]Th4+ at concentrations as low as 10-6 M, and serum stability experiments demonstrate the high kinetic stability of the formed complexes under biological conditions. Identical experiments with zirconium-89 (89Zr), a positron-emitting radioisotope used for positron emission tomography (PET) imaging, demonstrate that these chelators can also effectively bind Zr4+ with high thermodynamic and kinetic stability. Collectively, the data reported herein highlight the suitability of these ligands for use in 89Zr/227Th paired radioimmunotheranostics.

Siderocalin fusion proteins enable a new 86Y/90Y theranostic approach.

The mammalian protein siderocalin binds bacterial siderophores and their iron complexes through cation-π and electrostatic interactions, but also displays high affinity for hydroxypyridinone complexes of trivalent lanthanides and actinides. In order to circumvent synthetic challenges, the use of siderocalin-antibody fusion proteins is explored herein as an alternative targeting approach for precision delivery of trivalent radiometals. We demonstrate the viability of this approach in vivo, using the theranostic pair 90Y (ß-, t1/2 = 64 h)/86Y (ß+, t1/2 = 14.7 h) in a SKOV-3 xenograft mouse model. Ligand radiolabeling with octadentate hydroxypyridinonate 3,4,3-LI(1,2-HOPO) and subsequent protein binding were achieved at room temperature. The results reported here suggest that the rapid non-covalent binding interaction between siderocalin fusion proteins and the negatively charged Y(iii)-3,4,3-LI(1,2-HOPO) complexes could enable purification-free, cold-kit labeling strategies for the application of therapeutically relevant radiometals in the clinic.

Elemental chalcogen reactions of a tetravalent uranium imidophosphorane complex: cleavage of dioxygen.

Herein we report the first example of a mononuclear uranium complex, [U4+(NP(pip)3)4] (1-U), that selectively reduces dioxygen to produce a terminal oxo complex, [U6+O(NP(pip)3)4] (2-U; [NP(pip)3]1- is tris(piperidinyl)imidophosphorane). Reactions between 1-U and the heavier elemental chalcogens, S8 or Se0, result in six-coordinate U(VI) complexes, [U6+(κ2-E3)(NP(pip)3)4] (E = S (3-U) or Se (4-U)).

Chalcogen-atom abstraction reactions of a Di-iron imidophosphorane complex.

Reaction of the complexes [Fe2(µ2-NP(pip)3)2(NP(pip)3)2] (1-Fe) and [Co2(µ2-NP(pip)3)2(NP(pip)3)2] (1-Co), where [NP(pip)3]1- is tris(piperidinyl)imidophosphorane, with nitrous oxide, S8, or Se0 results in divergent reactivity. With nitrous oxide, 1-Fe forms [Fe2(µ2-O)(µ2-NP(pip)3)2(NP(pip)3)2] (2-Fe), with a very short Fe3+-Fe3+ distance. Reactions of 1-Fe with S8 or Se0 result in the bridging, side-on coordination (µ-κ1:κ1-E22-) of the heavy chalcogens in complexes [Fe2(µ-κ1:κ1-E2)(µ2-NP(pip)3)2(NP(pip)3)2] (E = S, 3-Fe, or Se, 4-Fe). In all cases, the complex 1-Co is inert.

Homoleptic cerium tris(dialkylamido)imidophosphorane guanidinate complexes.

We report the synthesis of a new potassium tris(piperdino)imidophosphorane N,N'-dicyclohexylguanidinate, K[CyGNP(pip)3], and describe the synthesis and characterization of the tris-homoleptic compounds, [Ce(CyGNP(pip)3)3], 1-Ce, and [Ce(CyGNP(pip)3)3][BPh4], 2-Ce. The latter is an unusual cationic tetravalent cerium complex. Cyclic voltammetry studies of 1-Ce and 2-Ce revealed Epc potentials of -1.56 V and -1.81 V, and Epa potentials of -0.78 V and -0.66 V (200 mV s-1; THF, vs. Fc0/+), respectively. Compounds 1-Ce and 2-Ce were studied by L3-edge X-ray absorption near-edge spectroscopy (XANES), and the fit of the spectrum of 2-Ce revealed a white-line multiplet with an nf value of 0.50(2).

Coinage metal tris(dialkylamido)imidophosphorane complexes as transmetallation reagents for cerium complexes.

We report the synthesis of tetrameric Cu(i) and Ag(i) homoleptic complexes supported by the tris(piperidinyl)imidophosphorane [NP(pip)3]1- and [NP(1,2-bis-tBu-diamidoethane)(NEt2)]1- ligands. These complexes demonstrate the redox stability of the imidophosphorane ligands to oxidizing salts, and the silver complexes can, in turn, serve as oxidative transmetallation reagents for the isolation of tetravalent cerium complexes from cerium metal or trivalent cerium precursors.

Diethyl ether adducts of trivalent lanthanide iodides.

The synthesis and structural characterization of the first molecular complexes of lanthanide iodides supported by the weak-base, diethyl ether, are reported. Single-crystal diffraction studies reveal a conserved [LnI3(mer-Et2O)3] structure (Ln = Ce, Pr, Nd, Sm, Gd, Tb, and Tm). These precursors are prepared from lanthanide metal and iodine in diethyl ether for all lanthanides La to Tm (excluding Pm and Eu) and provide the THF adducts in good to excellent (60-91%) yield in a two-step process.